Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Accumulated Expenses across 17 years of filings, most recently posting $25.5 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 6.25% year-over-year to $25.5 million; the TTM figure through Jun 2026 stood at $25.5 million (up 6.25% YoY), while the FY2025 annual figure was $33.2 million, up 23.8% from the prior year.
• Accumulated Expenses came in at $25.5 million for Q2 2026 at Ironwood Pharmaceuticals, down from $27.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $79.6 million in Q2 2023 to a low of $13.4 million in Q2 2022.
• Average Accumulated Expenses over 5 years is $31.8 million, with a median of $29.7 million recorded in 2024.
• Year-over-year, Accumulated Expenses soared 492.81% in 2023 and sank 59.28% in 2024.
• Over 5 years, Accumulated Expenses stood at $16.7 million in 2022, then soared by 164.99% to $44.3 million in 2023, then tumbled by 39.33% to $26.8 million in 2024, then gained by 23.8% to $33.2 million in 2025, then declined by 23.18% to $25.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $25.5 million in Q2 2026, $27.9 million in Q1 2026, and $33.2 million in Q4 2025.